The global cardiac ambulatory monitoring market enjoys a valuation of US$ 13.3 Billion in 2021, and it is further projected to expand at a CAGR of 5.2% over the forecast years. According to a recent study by Future Market Insights, ECG devices are leading the cardiac ambulatory monitoring market with a share of about 42.2 % in the year 2021.
Market Outlook:
| Data Points | Market Insight |
|---|---|
| Market Value 2021 | US$ 13.3 Billion |
| Estimated market Value 2022 | US$ 13.9 Billion |
| Estimated market Value 2032 | US$ 21.6 Billion |
| CAGR of 2022 to 2032 | 4.5 % |
| Market share of Top 5 countries | 61.3 % |
| Key Market players | Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, iRhythm Technologies Inc, Biotronik, Schiller, Medicomp Inc., Koninklijke Philips N.V., Applied Cardiac System, and MicroPort |
Ambulatory cardiac monitors are electrocardiograph devices that can record the heart's rhythm. The characteristics of these monitors vary depending on how long they can record and whether they can deliver recordings over the phone.
The majority of qualified professionals utilize ambulatory cardiac monitors to check heartbeat rate over time, correlate symptoms with the heartbeat, identify irregular heart rhythms, and examine additional symptoms a heart may present. With longer detection times and more accurate data, these devices provide assistance in heart monitoring.
Cardiac ambulatory monitoring devices help doctors identify irregular cardiac rhythms that occur occasionally and unexpectedly.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Between 2015 and 2021, the cardiac ambulatory monitoring market grew at a CAGR of 5.2%.
The global market for cardiac ambulatory monitoring held around 59.1% share within the global cardiac monitoring devices market, worth around US$ 22.5 Billion, in 2021.
Some of the most important CVD (cardiovascular disease) risk factors are family history, ethnicity, and age. Diabetes, inactivity, tobacco use, a poor diet, high cholesterol, obesity, high blood pressure (hypertension), and alcohol consumption are all risk factors. The prevalence of diseases like hypertension, diabetes, dyslipidemia, and obesity has increased due to changes in lifestyle, which also contributes to the global rise in the risk of CVD.
In the European Union, more than 60 million people have cardiovascular disease, and about 13 million new cases are diagnosed each year, according to statistics published by the European Society of Cardiology in June 2020. The market for cardiac ambulatory monitoring is anticipated to expand as a result of the rising prevalence of cardiovascular illnesses and the consequent rise in the demand for patient monitoring systems.
As per the data provided by WHO, cardiovascular diseases are the most common cause of death worldwide, claiming an average of 17.9 million lives yearly. Furthermore, according to the same data from the WHO, stroke and heart attacks account for the majority of deaths than other cardiovascular disease deaths, and the majority of these deaths are reported to happen before the age of 70. The majority of CVD deaths occur in growing economies.
The development of the market is anticipated to be fuelled by advanced product launches and strategic initiatives by major market competitors. For instance, in June 2021, AliveCor purchased CardioLabs, an industry-leading provider of monitoring and cardiac diagnostic services, from an independent diagnostic testing facility (IDTF). The acquisition was a key component of AliveCor's objective to offer a full range of cardiac diagnostic services to patients for whom their doctors have prescribed monitoring devices.
Thus, the above-mentioned factors are expected to act as possible market drivers to propel the global cardiac ambulatory monitoring market during the forecast period.
One of the main drivers of the growth of the cardiac ambulatory monitoring market is the usage of the most cutting-edge and minimally invasive surgical techniques to enhance patients' heart activity and amplify the results of various cardiac surgeries.
Furthermore, the market for cardiac ambulatory monitoring is predicted to grow as demand for advanced cardiac devices such as implantable loop recorders, event monitors, mobile cardiac telemetry, and Holter monitors grows. Additionally, favorable reimbursement practices, rising public and private healthcare spending, and other key aspects are driving the cardiac ambulatory monitoring market.
Cardiovascular monitoring devices have significantly improved as a result of recent advancements in heart monitoring equipment, particularly mobile cardiac telemetry (MCT) systems.
Moreover, to enhance CIED (cardiac implantable electronic devices) stability in the subcutaneous pocket and elute the antibiotics minocycline and rifampin, Medtronic offers an absorbable, multifilament mesh envelope (TYRX Absorbable Antibacterial Envelope).
Implantable cardioverter defibrillators (ICDs) and pacemakers are only a couple of examples of CIEDs that can be used with these envelopes. The envelope reduced the incidence of infection by 40% when compared to regular infection prevention alone.
The abovementioned factors are capable of serving as some lucrative opportunities for manufacturers operating in the cardiac ambulatory monitoring market.
Principal Consultant
When used to treat cardiac arrhythmias, CIEDs are linked to improved quality of life and survival rates. However, a significant risk factor for using these devices is CIED-associated infections. Patients with implantable cardioverter defibrillators or cardiac resynchronization therapy defibrillators are most likely to get CIED infections. The rate of CIED infections was 1.19% for pacemakers, 1.91% for implantable cardioverter-defibrillators, 2.18% for cardiac resynchronization therapy pacemakers (CRT-Ps), and 3.35% for CRT defibrillators, according to the European Heart Journal (CRTDs).
Medical device cybersecurity issues, particularly those in CIEDs that could be reprogrammed or rendered useless, are a major source of concern for both patients and healthcare professionals.
Mobile phones and mp3 players, metal detectors, magnets, high-voltage electrical wires, and electrical devices like toothbrushes, shavers, and microwaves can also hamper signals if the monitoring devices are in close proximity.
A growing number of cardiovascular surgeries has led to the use of ambulatory cardiac monitoring devices to continuously monitor cardiovascular patients in the USA. Ambulatory cardiac monitoring devices are currently required to track and monitor the heart to prevent fatal outcomes from cardiovascular diseases. Approximately 40,000 children in the USA. undergo congenital heart surgery each year, according to an article published in October 2020 titled, National Variation in Congenital Heart Surgery Outcomes.
ECG devices record heartbeats using electrical impulses, amplified and displayed on an ECG display. They are used to diagnose heart diseases and arrhythmias in a person and to help determine the most appropriate treatment. Electrocardiograms can be obtained at home with a portable ECG device, thanks to advances in technology. More than 60% of the global population suffers from cardiovascular diseases, according to the World Health Organization.
The ambulatory cardiac monitoring devices market in the USA. is consolidated, with the presence of a small number of leading players. Several companies are investing heavily in research and development activities, mainly to introduce advanced ambulatory cardiac monitoring devices to the market. To increase revenue and market share, key players form strategic alliances. They also diversify their product portfolios and acquire other companies.
There are several prominent players operating in the USA, ambulatory cardiac monitoring devices market, including Abbott Laboratories, Biotronik, Boston Scientific Corporation, Hill-Rom Holdings, GE Healthcare, Koninklijke Philips N.V., Medtronic, and Nihon Kohden Corporation.
The Portrait Mobile wireless patient monitoring system, announced by GE Healthcare in June 2022, provides continuous monitoring throughout a patient's stay. The system helps clinicians detect the deterioration of the patient. In addition to reducing the length of stay and ICU admissions, early detection of patient deterioration may improve patient outcomes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Germany dominates the European cardiac ambulatory monitoring market by achieving a valuation of US$ 0.79 Billion. This is despite retaining a market share of about 5.6% in the global market, in 2022. Europe is one of the largest markets for cardiac ambulatory monitoring across the globe. As the population ages, cardiac issues are on the rise.
Additionally, wearable devices for ambulatory cardiac monitors that incorporate advanced software, analytical tools, and artificial intelligence have been introduced to satisfy the increasing demand for holistic, multi-input, and patient-driven devices for complex physiology. As an example, Cambridge Heartware, a United Kingdom-based healthcare company, has introduced a wearable heart monitor that sends recorded data to the cloud so adaptive artificial intelligence algorithms can diagnose irregular heart rates that are clinically relevant.
Moreover, minimally invasive diagnostic tools and preventative healthcare devices are driving the market. In addition, governments in the region are creating awareness of cardiovascular disorders, which is driving the market forward.
Due to a large number of large, medium, and small players, the European cardiac monitoring market is extremely fragmented and specialized. To improve their market position, multinational players hold a substantial share of the cardiac monitoring market. To enhance their market presence, companies are focusing on several growth strategies, including mergers and acquisitions, partnerships, collaborations, and geographical expansions.
According to the forecast, Japan’s cardiac ambulatory monitoring market may grow at a CAGR of 3.1% in the forecasted period. The increasing cardiovascular disease burden and the increased adoption of minimally invasive procedures are driving the market growth in Japan's cardiac ambulatory monitoring market.
In December 2021, the National Cerebral and Cardiovascular Center, Japan, estimated that approximately 1.2 million Japanese people would suffer from heart failure by 2020. Additionally, based on the same source, heart failure patients are expected to increase in Japan, where people live to be 100 years old. This is because cardiovascular disease prevalence increases with age. Heart failure is one of the most prevalent conditions in Japan, which is expected to drive the adoption of cardiovascular devices.
Japan is also one of the nations with the fastest-aging population in the world. According to World Data 2022, there were 28% of people aged 65 and above in 2020 and 29% in 2021. The increase in the geriatric population in Japan is expected to drive market growth because geriatric people are more likely to suffer from chronic diseases like cardiovascular diseases.
Increased initiatives from key players in the market are also expected to drive market growth in Japan due to the rise in sales of cardiac ambulatory monitoring products. A distribution agreement between Rampart IC and Japan Lifeline (JLL) was signed in March 2022, securing distribution in the Japanese market. In addition to being designed for interventional cardiologists, the Rampart M1128 has been applied to a variety of interventional specialties.
As a result of these distribution partnerships, cardiovascular devices may be adopted more widely, driving market growth. For instance, As of January 2022, Medtronic's Micra AV Transcatheter Pacing System (TPS) has been approved and reimbursed by Japan's Ministry of Health, Labor, and Welfare. The company is preparing to launch the device.
The increasing prevalence of chronic diseases such as cardiovascular diseases among the population is expected to increase the demand for cardiac ambulatory monitoring devices, thereby propelling the cardiac ambulatory monitoring market growth in Korea. In addition, the growing geriatric population is also contributing to the market's growth.
According to the United Nations Population Fund's 2022 statistics, in Korea, 71% of the population is aged 15-64, which constitutes a large proportion of the living population. Additionally, according to the same source, 17% of the population will be 65 years or older by 2022. Thus, chronic disease is more likely to develop in the geriatric population.
Furthermore, the rising product launches and company activities in Korea are also expected to boost the cardiac ambulatory monitoring market over the forecast period. A South Korean healthcare start-up, Sky Labs, launched a wearable, ring-type heart rhythm monitoring device in November 2021 that detects atrial fibrillation (AF) and prevents heart-related problems. Additionally, Samsung launched in Korea a Health Monitoring Application, which can monitor blood pressure and ECGs.
As of 2021, the USA. held the greatest share of the global market at about 34.6% and generated revenue of around US$ 4.6 Billion. The country is anticipated to experience significant expansion as a result of positive government efforts, increased technological advancements, rising cardiovascular disease prevalence, and rapid economic growth. For instance, the geriatric population in the USA. is 16.8% of the total population, according to details published by the Organization for Economic Co-operation and Development in 2021. The market is expected to expand as a result of the rise in demand for cardiac pacemakers brought on by the aging population due to increasing incidences of cardiovascular issues.
In the European region, Germany dominates the cardiac ambulatory monitoring market by achieving a valuation of US$ 0.75 Billion withholding a market share of about 5.6% in the global market, in 2021. According to data published by the European Society of Cardiology in June 2020, more than 60 million people in the European Union have cardiovascular disease, and about 13 million new cases are diagnosed each year. The cardiac ambulatory monitoring market is anticipated to expand as a result of the rising incidence of cardiovascular disorders and the consequent rise in the requirement for cardiac ambulatory monitoring devices.
At the end of 2021, China held a market share of about 9.2% in the global cardiac ambulatory monitoring market. Cardiac ambulatory monitoring device adoption is particularly high in China. According to a study that was published in the Radcliffe Cardiology journal, heart failure is a serious health concern in China, where it appears to be more common than in Western nations. The market in the region is being driven by an increase in awareness of heart failure and the danger of sudden cardiac arrest associated with this disease.
In 2021, the ECG category contributed about 42.2% share of the global market 2021. This is explained by the fact that, as compared to other short- and long-term monitoring equipment, these devices provide a quicker and more accurate diagnosis of cardiac health. Additionally, compared to other devices, ECG devices have relatively lower pricing. These devices can also be utilized in medical operations, along with a variety of other cardiac diagnostic tests, telemetry monitoring equipment, and other tools.
Hospitals hold about US$ 4.7 Billion in revenue with 35.0% of the majority of the global market share in 2021. The rising incidence of CVDs, the rising number of hospital visits, the rising number of cardiac device implantation procedures, and the availability of reimbursement for these procedures, propel the expansion of this segment.
According to CDC (centers for disease control and prevention) report, in the USA., hospitals see about 6.9% of patients with ischemic heart disease, coronary artery disease, or a history of myocardial infarction each year, whereas emergency rooms see about 7.2% of patients with heart diseases.
The existence of numerous industry rivals has led to a slight fragmentation and concentration of the cardiac ambulatory monitoring market. Cardiac ambulatory monitoring devices offer a new paradigm in healthcare by gathering and analyzing long-term data for accurate diagnosis. These devices are becoming increasingly used for monitoring chronic heart disease.
The key manufacturers' strategic initiatives and the introduction of advanced products are anticipated to fuel the industry's expansion throughout the forecast period.
For Instance:
Similarly, recent developments related to companies manufacturing cardiac ambulatory monitoring products have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data Available for | 2015 to 2021 |
| Market Analysis | US$ Billion for Value, Volume (Units) |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA). |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Turkey, GCC Countries, South Africa, North Africa and Rest of Middle East and Africa(MEA). |
| Key Market Segments Covered | Product, end users, and regions |
| Key Companies Profiled | Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, iRhythm Technologies Inc, Biotronik, Schiller, Medicomp Inc., Koninklijke Philips N.V., Applied Cardiac System, MicroPort |
| Pricing | Available upon Request |
The global cardiac ambulatory monitoring market is worth US$ 13.3 Billion at end of 2021.
The cardiac ambulatory monitoring market is expected to reach US$ 21.6 Billion by end of 2032 at a CAGR of 4.5%.
Technology advancement in cardiac monitoring devices and increasing sedentary lifestyles among people leading to an increase in the prevalence of cardiovascular diseases are some of the key factors that drive this market.
The North American region has the highest market share of about 36.5% in 2021 in the global cardiac ambulatory monitoring market.
India accounted for about 6.6% of the market share in 2021 in the global cardiac ambulatory monitoring market.
The USA, China, Germany, Japan, and India are the top five countries, which are expected to drive demand in the cardiac ambulatory monitoring market.
Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, GE Healthcare, iRhythm Technologies Inc, Biotronik, Schiller, Medicomp Inc., Koninklijke Philips N.V., Applied Cardiac System, and MicroPort, are some of the key players in the cardiac ambulatory monitoring industry.
From 2015 to 2021, the market for cardiac ambulatory monitoring devices expanded at a CAGR of 5.2%.
China accounted for 9.2% of the market share at the end of 2021 in the global market.
Germany displayed a global market share of around 5.6% in 2021 in the cardiac ambulatory monitoring market.
1. Executive Summary | Cardiac Ambulatory Monitoring Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Key Promotional Strategies by Manufacturers
4.3. Regulatory Landscape
4.4. Reimbursement Scenario
4.5. Value Chain Analysis
4.6. Product Adoption Analysis
4.7. PESTEL Analysis
4.8. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Cardiac Monitoring Devices Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Increasing Complexity of Healthcare Operations
5.2.2. Product Pricing
5.2.3. Product Adoption
5.2.4. Rising Prevalence of Cardiovascular Diseases
5.2.5. Growing Volumes of Surgical Procedures
5.2.6. Product Licensing
5.2.7. Regulatory Scenario
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By End User
6.1.3. By Region
6.2. 2021 Market Scenario
7. Global Market Volume (Units) Analysis 2015 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Volume (Units) Analysis, 2015 to 2021
7.2. Current and Future Market Volume (Units) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
8. Global Market - Pricing Analysis
8.1. Regional Pricing Analysis, by Products
8.2. Pricing Break-up
8.2.1. Manufacturer-Level Pricing
8.2.2. Distributor Level Pricing
8.3. Global Average Pricing Analysis Benchmark
9. Global Market Demand (in Value or Size in US$ Billion) Analysis 2015 to 2021 and Forecast, 2022 to 2032
9.1. Historical Market Value (US$ Billion) Analysis, 2015 to 2021
9.2. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
9.2.1. Y-o-Y Growth Trend Analysis
9.2.2. Absolute $ Opportunity Analysis
10. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Product
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Billion) Analysis, by Product, 2015 to 2021
10.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by Product, 2022 to 2032
10.3.1. ECG Devices
10.3.2. Holter Monitors
10.3.3. Event Monitors
10.3.4. Implantable Loop Recorders
10.3.5. Mobile Cardiac Telemetry
10.4. Market Attractiveness Analysis, by Product
11. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Billion) Analysis, By End User, 2015 to 2021
11.3. Current and Future Market Size (US$ Billion) Analysis and Forecast, by End User, 2022 to 2032
11.3.1. Hospitals
11.3.2. Ambulatory Surgical Centers
11.3.3. Specialty Clinics
11.3.4. Cardiac Care Centers
11.3.5. Home Care Setting
11.4. Market Attractiveness Analysis, by End User
12. Global Market Analysis 2015 to 2021 and Forecast 2022 to 2032, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Billion) Analysis, by Region, 2015 to 2021
12.3. Current and Future Market Value (US$ Billion) Projections, 2022 to 2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis, by Region
13. North America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Billion) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
13.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Product
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product
13.4.3. By End User
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Country-Level Analysis & Forecast
13.7.1. USA Market Analysis
13.7.1.1. Introduction
13.7.1.2. Market Analysis and Forecast, by Market Taxonomy
13.7.1.2.1. By Product
13.7.1.2.2. By End User
13.7.2. Canada Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast, by Market Taxonomy
13.7.2.2.1. By Product
13.7.2.2.2. By End User
14. Latin America Market Analysis 2015 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Billion) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
14.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Product
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product
14.4.3. By End User
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. Mexico Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast, by Market Taxonomy
14.7.1.2.1. By Product
14.7.1.2.2. By End User
14.7.2. Brazil Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast, by Market Taxonomy
14.7.2.2.1. By Product
14.7.2.2.2. By End User
14.7.3. Argentina Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast, by Market Taxonomy
14.7.3.2.1. By Product
14.7.3.2.2. By End User
15. Europe Market Analysis 2015 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Billion) and Volume (Unit) Trend Analysis, by Market Taxonomy, 2015 to 2021
15.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Product
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product
15.4.3. By End User
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast, by Market Taxonomy
15.7.1.2.1. By Product
15.7.1.2.2. By End User
15.7.2. Italy Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast, by Market Taxonomy
15.7.2.2.1. By Product
15.7.2.2.2. By End User
15.7.3. France Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast, by Market Taxonomy
15.7.3.2.1. By Product
15.7.3.2.2. By End User
15.7.4. United Kingdom Cardiac Ambulatory Monitoring Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast, by Market Taxonomy
15.7.4.2.1. By Product
15.7.4.2.2. By End User
15.7.5. Spain Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast, by Market Taxonomy
15.7.5.2.1. By Product
15.7.5.2.2. By End User
15.7.6. BENELUX Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast, by Market Taxonomy
15.7.6.2.1. By Product
15.7.6.2.2. By End User
15.7.7. Russia Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast, by Market Taxonomy
15.7.7.2.1. By Product
15.7.7.2.2. By End User
16. East Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Billion) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
16.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Product
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product
16.4.3. By End User
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. China Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast, by Market Taxonomy
16.7.1.2.1. By Product
16.7.1.2.2. By End User
16.7.2. Japan Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast, by Market Taxonomy
16.7.2.2.1. By Product
16.7.2.2.2. By End User
16.7.3. South Korea Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast, by Market Taxonomy
16.7.3.2.1. By Product
16.7.3.2.2. By End User
17. South Asia Market Analysis 2015 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Billion) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
17.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Product
17.3.3. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product
17.4.3. By End User
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. India Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast, by Market Taxonomy
17.7.1.2.1. By Product
17.7.1.2.2. By End User
17.7.2. Indonesia Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast, by Market Taxonomy
17.7.2.2.1. By Product
17.7.2.2.2. By End User
17.7.3. Malaysia Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast, by Market Taxonomy
17.7.3.2.1. By Product
17.7.3.2.2. By End User
17.7.4. Thailand Market Analysis
17.7.4.1. Introduction
17.7.4.2. Market Analysis and Forecast, by Market Taxonomy
17.7.4.2.1. By Product
17.7.4.2.2. By End User
18. Oceania Market Analysis 2015 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Bn) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
18.3. Current and Future Market Value (US$ Billion) and Volume (Unit) Projections, 2022 to 2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Product
18.3.3. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Product
18.4.3. By End User
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. Australia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast, by Market Taxonomy
18.7.1.2.1. By Product
18.7.1.2.2. By End User
18.7.2. New Zealand Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast, by Market Taxonomy
18.7.2.2.1. By Product
18.7.2.2.2. By End User
19. Middle East and Africa (MEA) Market Analysis 2015 to 2021 and Forecast 2022 to 2032
19.1. Introduction
19.2. Historical Market Size (US$ Billion) and Volume (Unit) Analysis Trend Analysis, by Market Taxonomy, 2015 to 2021
19.3. Current and Future Market Value (US$ Bn) and Volume (Unit) Projections, 2022 to 2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. South Africa
19.3.1.4. North Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Product
19.3.3. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Product
19.4.3. By End User
19.5. Market Trends
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. GCC Countries Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast, by Market Taxonomy
19.7.1.2.1. By Product
19.7.1.2.2. By End User
19.7.2. Turkey Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast, by Market Taxonomy
19.7.2.2.1. By Product
19.7.2.2.2. By End User
19.7.3. South Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast, by Market Taxonomy
19.7.3.2.1. By Product
19.7.3.2.2. By End User
19.7.4. North Africa Market
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast, by Market Taxonomy
19.7.4.2.1. By Product
19.7.4.2.2. By End User
20. Market Structure Analysis
20.1. Market Analysis, by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Medtronic Public Health Company
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Profitability by Market Segments (Product/Channel/Region)
21.3.1.4. Sales Footprint
21.3.1.5. Key Financials
21.3.1.6. SWOT Analysis
21.3.1.7. Strategy Overview
21.3.2. Abbott Laboratories
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Profitability by Market Segments (Product/Channel/Region)
21.3.2.4. Sales Footprint
21.3.2.5. Key Financials
21.3.2.6. SWOT Analysis
21.3.2.7. Strategy Overview
21.3.3. Boston Scientific Corporation
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Profitability by Market Segments (Product/Channel/Region)
21.3.3.4. Sales Footprint
21.3.3.5. Key Financials
21.3.3.6. SWOT Analysis
21.3.3.7. Strategy Overview
21.3.4. GE Healthcare
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Profitability by Market Segments (Product/Channel/Region)
21.3.4.4. Sales Footprint
21.3.4.5. Key Financials
21.3.4.6. SWOT Analysis
21.3.4.7. Strategy Overview
21.3.5. iRhythm Technologies Inc.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Profitability by Market Segments (Product/Channel/Region)
21.3.5.4. Sales Footprint
21.3.5.5. Key Financials
21.3.5.6. SWOT Analysis
21.3.5.7. Strategy Overview
21.3.6. Biotronik
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Profitability by Market Segments (Product/Channel/Region)
21.3.6.4. Sales Footprint
21.3.6.5. Key Financials
21.3.6.6. SWOT Analysis
21.3.6.7. Strategy Overview
21.3.7. Schiller
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Profitability by Market Segments (Product/Channel/Region)
21.3.7.4. Sales Footprint
21.3.7.5. Key Financials
21.3.7.6. SWOT Analysis
21.3.7.7. Strategy Overview
21.3.8. Medicomp Inc.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Profitability by Market Segments (Product/Channel/Region)
21.3.8.4. Sales Footprint
21.3.8.5. Key Financials
21.3.8.6. SWOT Analysis
21.3.8.7. Strategy Overview
21.3.9. Koninklijke Philips N.V.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Profitability by Market Segments (Product/Channel/Region)
21.3.9.4. Sales Footprint
21.3.9.5. Key Financials
21.3.9.6. SWOT Analysis
21.3.9.7. Strategy Overview
21.3.10. Applied Cardiac System
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Profitability by Market Segments (Product/Channel/Region)
21.3.10.4. Sales Footprint
21.3.10.5. Key Financials
21.3.10.6. SWOT Analysis
21.3.10.7. Strategy Overview
21.3.11. MicroPort
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Profitability by Market Segments (Product/Channel/Region)
21.3.11.4. Sales Footprint
21.3.11.5. Key Financials
21.3.11.6. SWOT Analysis
21.3.11.7. Strategy Overview
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Cardiac Ambulatory Monitoring Market
